Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

The company delivered a convincing pair of beats in its third-quarter earnings report.

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65.

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week highs. As of late 2025, pharmaceutical giant Eli Lilly, defense and safety solutions provider Cadre Holdings, energy major BP, global food company Kellanova, and

Teva stock jumped Wednesday on better-than-expected quarterly metrics.

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock

Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally

Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Druckenmiller is considered one of the best investors of all time.

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

Duquesne Family Office's billionaire boss bid adieu to Wall Street's hottest AI stocks in favor of another trillion-dollar company and a long-awaited turnaround story in the healthcare sector.

Trump administration to announce concerns about Tylenol use in pregnancy and potential treatment for autism, in line with President's priority.

Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors.

The global trade landscape has once again been rattled as the United States officially implemented sweeping new tariffs on a significant portion of imports from India. Effective August 27, 2025, these duties, which now stand at a steep 50%, signal a dramatic re-emergence of protectionist policies that many feared would

Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy.

Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs.